Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4562 ARTÍCULOS , VIENDO DEL 1711 AL 1725

[Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study]

Jost WH, Kupsch A, Mengs J, Delf M, Bosse D.

Fortschr Neurol Psychiatr. 2018 Oct;86(10):624-634. doi: 10.1055/a-0665-4667. Epub 2018 Aug 24.

Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease

Shen Z, Kong D.

Medicine (Baltimore). 2018 Aug;97(34):e11316. doi: 10.1097/MD.0000000000011316.

Diagnostic biomarkers for Parkinson's disease at a glance: where are we?

Cova I, Priori A.

J Neural Transm (Vienna). 2018 Oct;125(10):1417-1432. doi: 10.1007/s00702-018-1910-4. Epub 2018 Aug 25.

Ferroptosis, a Recent Defined Form of Critical Cell Death in Neurological Disorders

Wu JR, Tuo QZ, Lei P.

J Mol Neurosci. 2018 Oct;66(2):197-206. doi: 10.1007/s12031-018-1155-6. Epub 2018 Aug 25.

Validation of the MDS clinical diagnostic criteria for Parkinson's disease

Postuma RB, Poewe W, Litvan I, Lewis S, Lang AE, Halliday G, Goetz CG, Chan P, Slow E, Seppi K, Schaffer E, Rios-Romenets S, Mi T, Maetzler C, Li Y, Heim B, Bledsoe IO, Berg D.

Mov Disord. 2018 Oct;33(10):1601-1608. doi: 10.1002/mds.27362. Epub 2018 Aug 25.

Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice

Mestre TA, Shamy M, Benedetti F, Lang AE.

Mov Disord. 2018 Aug;33(8):1195-1203. doi: 10.1002/mds.27409. Epub 2018 Aug 25.

Modulation of the Motor System by Placebo and Nocebo Effects

Fiorio M.

Int Rev Neurobiol. 2018;139:297-319. doi: 10.1016/bs.irn.2018.07.012. Epub 2018 Aug 7.

Nocebo Responses in Brain Diseases: A Systematic Review of the Current Literature

Zis P, Mitsikostas DD.

Int Rev Neurobiol. 2018;139:443-462. doi: 10.1016/bs.irn.2018.07.025. Epub 2018 Aug 2.

Herbal and Holistic Solutions for Neurodegenerative and Depressive Disorders: Leads from Ayurveda

Sharma R, Kabra A, Rao MM, Prajapati PK.

Curr Pharm Des. 2018;24(22):2597-2608. doi: 10.2174/1381612824666180821165741.

Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells

Li H, Jiang H, Zhang B, Feng J.

J Parkinsons Dis. 2018;8(4):479-493. doi: 10.3233/JPD-181353.

Crime and Parkinson's: The jury is out

Santens P, De Letter M, Lees AJ, Krack P, van den Heuvel OA, Bloem BR.

Mov Disord. 2018 Jul;33(7):1092-1094. doi: 10.1002/mds.27436.

Persistent adverse effects following different targets and periods after bilateral deep brain stimulation in patients with Parkinson's disease

Yin Z, Cao Y, Zheng S, Duan J, Zhou D, Xu R, Hong T, Lu G.

J Neurol Sci. 2018 Oct 15;393:116-127. doi: 10.1016/j.jns.2018.08.016. Epub 2018 Aug 18.

Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis

Qureshi AR, Rana AQ, Malik SH, Rizvi SFH, Akhter S, Vannabouathong C, Sarfraz Z, Rana R.

Neuroepidemiology. 2018;51(3-4):190-206. doi: 10.1159/000492221. Epub 2018 Aug 28.

Self-report data as a tool for subtype identification in genetically-defined Parkinson's Disease

Winslow AR, Hyde CL, Wilk JB, Eriksson N, Cannon P, Miller MR, Hirst WD.

Sci Rep. 2018 Aug 28;8(1):12992. doi: 10.1038/s41598-018-30843-6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias